Raymond James Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $124
Raymond James analyst Steven Seedhouse maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target from $127 to $124.
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
EF Hutton Initiates Coverage On Intellia Therapeutics with Buy Rating, Announces Price Target of $130
EF Hutton analyst Michael King initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Buy rating and announces Price Target of $130.
Intellia Therapeutics To Present Updated Interim Clinical Data From Ongoing Phase 1/2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2022 ACAAI Annual Scientific Meeting
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract
JP Morgan Initiates Coverage On Intellia Therapeutics with Overweight Rating, Announces Price Target of $85
JP Morgan analyst Brian Cheng initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Overweight rating and announces Price Target of $85.
JMP Securities Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $111
JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and raises the price target from $106 to $111.
This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedEx
Wells Fargo lowered the price target for Adobe Inc. (NASDAQ: ADBE) from $425 to $310. Adobe shares fell 1.2% to $296.04 in pre-market trading.
SVB Leerink Maintains Outperform on Intellia Therapeutics, Raises Price Target to $158
SVB Leerink analyst Mani Foroohar maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and raises the price target from $152 to $158.
UPDATE: ‘Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28’
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Sept. 16, 2022 /PRNewswire/ -- Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim
Intellia Therapeutics Announces Upcoming Investor Event To Present Interim Clinical Data From Ongoing First-In-Human Studies Of NTLA-2002 And NTLA-2001 On September 16
Review of first clinical data from ongoing Phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema (HAE) presented at the 2022 Bradykinin Symposium
Event to include interim safety and serum TTR